Related Experiment Video
Updated: Sep 16, 2025
08:05
A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation
Published on: June 8, 2018
11.6K
Computed tomography-guided irreversible electroporation for a pubic bone metastasis: a technical note and early
Claudio Pusceddu1, Eliodoro Faiella2, Claudio Cau1
1Mater Olbia Hospital, Clinic of Radiology, Olbia, Italy
Summary
Irreversible electroporation, a non-thermal ablation method, shows promise for treating bone metastases, especially in difficult locations where thermal ablation is limited. Further research is needed to establish its efficacy and safety for bone lesions.
Area of Science:
- Oncology
- Interventional Radiology
- Biomedical Engineering
Background:
- Bone metastases are a frequent complication of advanced solid tumors.
- Local control of bone metastases is crucial alongside systemic therapy.
- Thermal ablation is effective but limited in complex or heat-sensitive bone locations.
Purpose of the Study:
- To explore the potential of irreversible electroporation (IRE) for treating bone metastases.
- To evaluate IRE as a novel, non-thermal ablative option for bone lesions.
- To address the limitations of thermal ablation in specific anatomical sites.
Main Methods:
- Review of existing literature on IRE in visceral oncology.
- Analysis of the principles of IRE and its applicability to bone tissue.
- Discussion of potential benefits and challenges of IRE for bone metastases.
Main Results:
- Irreversible electroporation is a non-thermal ablation technique successfully used in visceral oncology.
- No previous reports exist on the application of IRE for bone metastases treatment.
- IRE's non-thermal nature may overcome limitations of thermal methods in sensitive bone areas.
Conclusions:
- Irreversible electroporation presents a potential new therapeutic strategy for bone metastases.
- Further investigation is warranted to establish the safety and efficacy of IRE in treating bone metastases.
- This technique could expand local control options for patients with bone metastases.
